Meril Presents One-Year Results of LANDMARK RCT at EuroPCR 2025
Vapi, 24th May 2025– Meril Life Sciences today announced one-year results from its pivotal LANDMARK trial, presented during the prestigious Late-Breaking Trial session at EuroPCR 2025,one of the world's premier cardiology conferences held annually in Paris, France.The LANDMARK trial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis.
The Myval THV series demonstrated non-inferiority to contemporary THVs in terms of 1-year clinical efficacy composite endpoint (Myval THV Series: 13% vs. Contemporary THV: 13.1%, difference: -0.1%, one-sided 95% CI: 3.9%, Pnoninferiority < 0.0001).
Additionally, in the composite endpoint of clinical efficacy combined with QoL, outcomes were comparable (Myval THV Series: 19.5% vs. Contemporary THVs: 22.7%, difference: -3.2%, 95% CI: -9.2 to 2.9, P=0.33). Hemodynamic parameters including effective orifice area (EOA), mean pressure gradient (PG), and incidence of moderate or greater aortic regurgitation remained stable and similar across all treatment arms.
Survival rates were nearly identical (Myval THV Series: 92.8% vs. Contemporary THVs: 92.9%), and QoL improvements were comparable, reinforcing the overall safety and durability of the Myval THV series in everyday clinical use.
Professor Patrick Serruys,Chairman and Study Director of the LANDMARKtrial, said:'This trial reflects a new era in comparative valve research. The meticulous design and adherence to VARC-3 standards, including QoL endpoints, mark it as a pivotal study. The results of the LANDMARKtrial represent a meaningful advancement for the global structural heart community—and most importantly, for patients receiving TAVI. The data not only validate the safety and efficacy of the Myval THV series, but also spotlight its adaptability to complex anatomies. This versatility is exactly what clinicians need to deliver precision care across a broad spectrum of patients.' Meril
Professor Andreas Baumbach,Global Principal Investigator, said: 'The LANDMARK trial represents a significant step forward in TAVI research. For the first time, we've benchmarked Myval against both balloon-expandable and self-expanding platforms in a rigorous randomized setting. The one-year results demonstrates that the new generation Myval THV series can match global standards in safety and efficacy.'
Mr. Sanjeev Bhatt,Senior Vice President – Corporate Strategy at Meril, said:'The LANDMARKtrial represents a significant milestone not just for Meril, but for the global TAVI community. The strong one-year results affirm the Myval THV series as a next-generation solution that delivers consistent safety, clinical efficacy, and improved quality of life across geographies. As the only head-to-head trial of its kind to include both balloon-expandable and self-expanding valves, it reinforces Myval THV series's versatility and real-world relevance for diverse patient anatomies and healthcare systems. At Meril, we are proud to contribute innovative, evidence-based technologies that are reshaping patient care and expanding access to advanced structural heart therapies worldwide.'
The trial is designed to follow patients for a period of 10 years, aiming to generate long-term insights into clinical and echocardiographic outcomes, with a focus on valve durability and sustained performance.
The LANDMARKtrial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis. The LANDMARKtrial was a prospective, randomized, multicenter, open-label, non-inferiority trial involving 768 patients who underwent Transcatheter Aortic Valve Implantation (TAVI) for the treatment of aortic stenosis. The first patient was enrolled in the LANDMARKtrial on 6 January 2021 and the last patient was enrolled on 5 December 2023. The trial included a total of 768 patients at 31 sites across 16 countries (Brazil, New Zealand, and some countries of Europe). The 30-day primary composite endpoints highlighting the safety and efficacy outcomes of the LANDMARKtrial have been successfully published in The Lancet and EuroIntervention, two of the most prestigious peer-reviewed medical journals.
Meril is a global medical device company based in India, committed to advancing healthcare through innovation. With a strong focus on research and development, Meril delivers cutting-edge medtech solutions across more than 135 countries and has a robust presence through subsidiaries in the USA, Brazil, Europe, Asia, Africa, and Australia. Through partnerships, precision technology, and adherence to international quality standards, Meril is helping reshape the future of healthcare.
Note to readers: This article is part of Mint's paid consumer connect Initiative. Mint assumes no editorial involvement or responsibility for errors, omissions, or content accuracy.
Want to get your story featured as above? click here!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
7 days ago
- Fashion Value Chain
S.L. Raheja Hospital, Mumbai Completes 50 TAVI Procedures, Showcasing Excellence Minimally Invasive Heart Solutions
This milestone marks a major leap in delivering safer, faster, and more effective heart valve treatment for elderly and high-risk patients, setting high benchmarks for the hospitals Structural Heart Program In addition to its excellence in Cardiology, S.L. Raheja Hospital-a quaternary care center in Mumbai-offers advanced care in Oncology, Neurology, Orthopedics, Critical Care, Diabetology, and other specialties, ensuring comprehensive, patient-centered treatment Clinicians at the Department of Interventional Cardiology and Structural Heart Intervention at S.L. Raheja Hospital, Mahim – A Fortis Associate have successfully performed 50 Transcatheter Aortic Valve Implantation (TAVI) procedures – marking a significant milestone for cardiac care in the Mumbai region. This milestone puts S.L. Raheja Hospital, Mahim, at the forefront of cardiac care in Mumbai, with one of Mumbai's most advanced Structural Heart Programs. The milestone was achieved under the leadership of Dr. Haresh Mehta, Director – Interventional Cardiology and Structural Heart Interventions, along with Consultant – Interventional Cardiologists Dr. Kayan Siodia and Dr. Raghav Nagpal. (L-R) Dr Raghav Nagpal, Dr Haresh Mehta & Dr Kayan Siodia, Interventional Cardiology & Structural Heart Team at S.L. Raheja Hospital, Mumbai – A Fortis Associate TAVI is a minimally invasive procedure used to replace a narrowed Aortic Valve that fails to open properly, a condition known as Aortic Stenosis. It can be potentially life-changing for elderly and high-risk patients who are not suitable for open-heart surgery. Among the 50 procedures performed, the team has successfully navigated many complex cases – including bicuspid aortic valves (typically more challenging due to having two cusps instead of three) and extremely narrow femoral arteries, sometimes as small as 4.95 mm. In rare cases where femoral access was not feasible, the team has also performed trans carotid (neck-access) TAVIs with excellent results – demonstrating both technical expertise and adherence to standardized global best practices. Talking about the benefits of TAVI, Dr. Haresh Mehta, Director – Interventional Cardiology and Structural Heart Interventions, S.L. Raheja Hospital, Mahim – A Fortis Associate, said, 'Severe symptomatic Aortic Stenosis can limit a patient's life expectancy to just 2-to-5 years. Thus, TAVI, the procedure used to treat this condition, can bring about life-altering changes as it extends life, and also dramatically improves quality of life. Since it is minimally invasive, patients often feel relief within 24 hours of the procedure and are discharged within 48 hours – all without the need for open surgery, sutures, or any long recovery times. While TAVI is a key cardiac procedure, patients also benefit from a range of advanced treatments for other heart conditions, including pacemaker implantation, structural heart interventions, and coronary angioplasties.' Talking about the milestone, Dr. Kunal Punamiya, CEO, S.L. Raheja Hospital, Mahim – A Fortis Associate, said, 'This momentous achievement reflects our ongoing commitment to delivering cutting-edge cardiac interventions to those who need it the most. With this milestone, we continue to deliver world-class minimally invasive cardiac care that ensures improved outcomes, faster recovery, and enhanced quality of life. Our Structural Heart Program has been designed to provide cutting-edge cardiac therapies under one roof, which includes stenting and Angioplasty, Atherectomy, ICD and Pacemaker implantation, valve repair, and more. Additionally, we are equipped with a state-of-the-art Cath lab to support these advanced procedures.' This clinical achievement, like many others at S.L. Raheja Hospital Mumbai, reflect the hospital's unwavering commitment to compassionate care. It's milestones like these that allow the teams to keep pushing boundaries and touching lives – one patient at a time. About Fortis Healthcare Limited Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organizations in the country with 27 healthcare facilities, ~4,750 operational beds (including O&M facilities), and over 400 diagnostics centers (including JVs). The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with a global major and parent company – IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs over 23,000 people (including Agilus Diagnostics Limited) who share its vision of becoming the world's most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.
Time of India
25-05-2025
- Time of India
Scientists have lost their jobs or grants in US cuts. Foreign universities want to hire them
As the Trump administration cut billions of dollars in federal funding to scientific research, thousands of scientists in the U.S. lost their jobs or grants - and governments and universities around the world spotted an opportunity. The "Canada Leads" program, launched in April, hopes to foster the next generation of innovators by bringing early-career biomedical researchers north of the border. Aix-Marseille University in France started the "Safe Place for Science" program in March - pledging to "welcome" U.S.-based scientists who "may feel threatened or hindered in their research." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Write Better, Work Smarter With This Desktop App Grammarly Install Now Undo Australia's "Global Talent Attraction Program," announced in April, promises competitive salaries and relocation packages. "In response to what is happening in the U.S.," said Anna-Maria Arabia, head of the Australian Academy of Sciences, "we see an unparalleled opportunity to attract some of the smartest minds here." Live Events Since World War II, the U.S. has invested huge amounts of money in scientific research conducted at independent universities and federal agencies. That funding helped the U.S. to become the world's leading scientific power - and has led to the invention of cell phones and the internet as well as new ways to treat cancer, heart disease and strokes, noted Holden Thorp, editor-in-chief of the journal Science. But today that system is being shaken. Since President Donald Trump took office in January, his administration has pointed to what it calls waste and inefficiency in federal science spending and made major cuts to staff levels and grant funding at the National Science Foundation, the National Institutes of Health, NASA and other agencies, as well as slashing research dollars that flow to some private universities. The White House budget proposal for next year calls to cut the NIH budget by roughly 40% and the National Science Foundation's by 55%. "The Trump administration is spending its first few months reviewing the previous administration's projects, identifying waste, and realigning our research spending to match the American people's priorities and continue our innovative dominance," said White House spokesperson Kush Desai. Already, several universities have announced hiring freezes, laid off staff or stopped admitting new graduate students. On Thursday, the Trump administration revoked Harvard University 's ability to enroll international students, though a judge put that on hold. Research institutions abroad are watching with concern for collaborations that depend on colleagues in the U.S. - but they also see opportunities to potentially poach talent. "There are threats to science ... south of the border," said Brad Wouters, of University Health Network, Canada's leading hospital and medical research center, which launched the "Canada Leads" recruitment drive. "There's a whole pool of talent, a whole cohort that is being affected by this moment." Promising a safe place to do science Universities worldwide are always trying to recruit from one another, just as tech companies and businesses in other fields do. What's unusual about the current moment is that many global recruiters are targeting researchers by promising something that seems newly threatened: academic freedom. European Commission President Ursula von der Leyen said this month that the European Union intends "to enshrine freedom of scientific research into law." She spoke at the launch of the bloc's "Choose Europe for Science" - which was in the works before the Trump administration cuts but has sought to capitalize on the moment. Eric Berton, president of Aix-Marseille University, expressed a similar sentiment after launching the institution's "Safe Place for Science" program. "Our American research colleagues are not particularly interested by money," he said of applicants. "What they want above all is to be able to continue their research and that their academic freedom be preserved." Too early to say 'brain drain' It's too early to say how many scientists will choose to leave the U.S. It will take months for universities to review applications and dole out funding, and longer for researchers to uproot their lives. Plus, the American lead in funding research and development is enormous - and even significant cuts may leave crucial programs standing. The U.S. has been the world's leading funder of R&D - including government, university and private investment - for decades. In 2023, the country funded 29% of the world's R&D, according to the American Association for the Advancement of Science. But some institutions abroad are reporting significant early interest from researchers in the U.S. Nearly half of the applications to "Safe Place for Science" - 139 out of 300 total - came from U.S.-based scientists, including AI researchers and astrophysicists. U.S.-based applicants in this year's recruitment round for France's Institute of Genetics, Molecular and Cellular Biology roughly doubled over last year. At the Max Planck Society in Germany, the Lise Meitner Excellence Program - aimed at young female researchers - drew triple the number of applications from U.S.-based scientists this year as last year. Recruiters who work with companies and nonprofits say they see a similar trend. Natalie Derry, a U.K.-based managing partner of the Global Emerging Sciences Practice at recruiter WittKieffer, said her team has seen a 25% to 35% increase in applicants from the U.S. cold-calling about open positions. When they reach out to scientists currently based in the U.S., "we are getting a much higher hit rate of people showing interest." Still, there are practical hurdles to overcome for would-be continent-hoppers, she said. That can include language hurdles, arranging childcare or eldercare, and significant differences in national pension or retirement programs. Community ties Brandon Coventry never thought he would consider a scientific career outside the United States. But federal funding cuts and questions over whether new grants will materialize have left him unsure. While reluctant to leave his family and friends, he's applied to faculty positions in Canada and France. "I've never wanted to necessarily leave the United States, but this is a serious contender for me," said Coventry, who is a postdoctoral fellow studying neural implants at the University of Wisconsin-Madison. But it's not easy to pick up and move a scientific career - let alone a life. Marianna Zhang was studying how children develop race and gender stereotypes as a postdoctoral fellow at New York University when her National Science Foundation grant was canceled. She said it felt like "America as a country was no longer interested in studying questions like mine." Still, she wasn't sure of her next move. "It's no easy solution, just fleeing and escaping to another country," she said. The recruitment programs range in ambition, from those trying to attract a dozen researchers to a single university to the continent-wide "Choose Europe" initiative. But it's unclear if the total amount of funding and new positions offered could match what's being shed in the U.S. A global vacuum Even as universities and institutes think about recruiting talent from the U.S., there's more apprehension than glee at the funding cuts. "Science is a global endeavor," said Patrick Cramer, head of the Max Planck Society, noting that datasets and discoveries are often shared among international collaborators. One aim of recruitment drives is to "to help prevent the loss of talent to the global scientific community," he said. Researchers worldwide will suffer if collaborations are shut down and databases taken offline, scientists say. "The U.S. was always an example, in both science and education," said Patrick Schultz, president of France's Institute of Genetics, Molecular and Cellular Biology. So the cuts and policies were "very frightening also for us because it was an example for the whole world."
Mint
24-05-2025
- Mint
Meril Presents One-Year Results of LANDMARK RCT at EuroPCR 2025
Vapi, 24th May 2025– Meril Life Sciences today announced one-year results from its pivotal LANDMARK trial, presented during the prestigious Late-Breaking Trial session at EuroPCR 2025,one of the world's premier cardiology conferences held annually in Paris, LANDMARK trial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis. The Myval THV series demonstrated non-inferiority to contemporary THVs in terms of 1-year clinical efficacy composite endpoint (Myval THV Series: 13% vs. Contemporary THV: 13.1%, difference: -0.1%, one-sided 95% CI: 3.9%, Pnoninferiority < 0.0001). Additionally, in the composite endpoint of clinical efficacy combined with QoL, outcomes were comparable (Myval THV Series: 19.5% vs. Contemporary THVs: 22.7%, difference: -3.2%, 95% CI: -9.2 to 2.9, P=0.33). Hemodynamic parameters including effective orifice area (EOA), mean pressure gradient (PG), and incidence of moderate or greater aortic regurgitation remained stable and similar across all treatment arms. Survival rates were nearly identical (Myval THV Series: 92.8% vs. Contemporary THVs: 92.9%), and QoL improvements were comparable, reinforcing the overall safety and durability of the Myval THV series in everyday clinical use. Professor Patrick Serruys,Chairman and Study Director of the LANDMARKtrial, said:'This trial reflects a new era in comparative valve research. The meticulous design and adherence to VARC-3 standards, including QoL endpoints, mark it as a pivotal study. The results of the LANDMARKtrial represent a meaningful advancement for the global structural heart community—and most importantly, for patients receiving TAVI. The data not only validate the safety and efficacy of the Myval THV series, but also spotlight its adaptability to complex anatomies. This versatility is exactly what clinicians need to deliver precision care across a broad spectrum of patients.' Meril Professor Andreas Baumbach,Global Principal Investigator, said: 'The LANDMARK trial represents a significant step forward in TAVI research. For the first time, we've benchmarked Myval against both balloon-expandable and self-expanding platforms in a rigorous randomized setting. The one-year results demonstrates that the new generation Myval THV series can match global standards in safety and efficacy.' Mr. Sanjeev Bhatt,Senior Vice President – Corporate Strategy at Meril, said:'The LANDMARKtrial represents a significant milestone not just for Meril, but for the global TAVI community. The strong one-year results affirm the Myval THV series as a next-generation solution that delivers consistent safety, clinical efficacy, and improved quality of life across geographies. As the only head-to-head trial of its kind to include both balloon-expandable and self-expanding valves, it reinforces Myval THV series's versatility and real-world relevance for diverse patient anatomies and healthcare systems. At Meril, we are proud to contribute innovative, evidence-based technologies that are reshaping patient care and expanding access to advanced structural heart therapies worldwide.' The trial is designed to follow patients for a period of 10 years, aiming to generate long-term insights into clinical and echocardiographic outcomes, with a focus on valve durability and sustained performance. The LANDMARKtrial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis. The LANDMARKtrial was a prospective, randomized, multicenter, open-label, non-inferiority trial involving 768 patients who underwent Transcatheter Aortic Valve Implantation (TAVI) for the treatment of aortic stenosis. The first patient was enrolled in the LANDMARKtrial on 6 January 2021 and the last patient was enrolled on 5 December 2023. The trial included a total of 768 patients at 31 sites across 16 countries (Brazil, New Zealand, and some countries of Europe). The 30-day primary composite endpoints highlighting the safety and efficacy outcomes of the LANDMARKtrial have been successfully published in The Lancet and EuroIntervention, two of the most prestigious peer-reviewed medical journals. Meril is a global medical device company based in India, committed to advancing healthcare through innovation. With a strong focus on research and development, Meril delivers cutting-edge medtech solutions across more than 135 countries and has a robust presence through subsidiaries in the USA, Brazil, Europe, Asia, Africa, and Australia. Through partnerships, precision technology, and adherence to international quality standards, Meril is helping reshape the future of healthcare. Note to readers: This article is part of Mint's paid consumer connect Initiative. Mint assumes no editorial involvement or responsibility for errors, omissions, or content accuracy. Want to get your story featured as above? click here!
